1. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study.
- Author
-
Delgado E, León-Ponte M, Villahermosa ML, Cuevas MT, Deibis L, Echeverría G, Thomson MM, Pérez-Alvarez L, Osmanov S, and Nájera R
- Subjects
- Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, Drug Resistance, Microbial, Drug Therapy, Combination, Female, HIV Infections drug therapy, HIV Infections epidemiology, HIV-1 drug effects, Humans, Male, Molecular Sequence Data, Mutation, Phylogeny, Protease Inhibitors therapeutic use, Reverse Transcriptase Inhibitors therapeutic use, Venezuela epidemiology, HIV Infections virology, HIV Protease genetics, HIV Reverse Transcriptase genetics, HIV-1 genetics
- Abstract
We report the first study on prevalence of antiretroviral drug-associated resistance mutations in Venezuela. Protease and reverse transcriptase (RT) coding regions were analyzed in DNA samples obtained from 100 HIV-1-infected individuals. Primary resistance mutations to RT inhibitors were identified in 26% of patients treated with these drugs. Transmission of HIV-1-resistant strains was detected in a drug-naive patient (3%). Primary resistance mutations to protease inhibitors (PIs) were present in 9% of the 44 PI-treated patients and in 1 PI-naive individual. Phylogenetic analysis of these samples has resulted in the most extensive survey, to date, of HIV-1 genetic forms circulating in Venezuela. Ninety-nine samples clustered with subtype B, and 1 individual harbored the first B/F recombinant virus reported in Venezuela, with protease clustering with subtype F and RT with subtype B. In addition, this isolate had a new insertion (Glu-34 duplication) in the protease gene.
- Published
- 2001
- Full Text
- View/download PDF